Ipsen SA plucked Canbex Therapeutics Ltd. in its prime, gaining an exclusive option to purchase the small University College London (UCL) spin-off and forestall a potential competitor to its Dysport (abobotulinumtoxin A) franchise to treat spasticity across a range of neuromuscular conditions.